MN-AYMIUM
6.6.2024 13:01:27 CEST | Business Wire | Press release
Aymium, the leading producer of renewable biocarbon products, announced today that it closed $210 Million of financing to construct a biocarbon production facility in Williams, California. The facility will support the first large-scale continuous use of advanced biocarbon to replace coal in power generation in the world. Use of the product from the Williams facility to replace coal will reduce greenhouse gas emissions by over 500,000 metric tons per year—equivalent to removing over 120,000 cars from the road annually. Construction of the facility is scheduled to be completed in 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606231738/en/
Aymium's reactor being delivered to the new biocarbon production facility in Williams, CA. The biocarbon will replace coal in power generation around the world and reduce greenhouse gas emissions by more than 500,000 metric tons per year, equivalent to removing 120,000 cars annually. (Photo: Business Wire)
“We are excited to have the support from such an experienced group of investors from Asia, North America and Europe,” said James Mennell, CEO of Aymium. “These groups share a profound commitment to decarbonization and have come together to advance this technology that will create a substantial reduction in greenhouse gas emissions for many years.”
The facility will be funded by a global group of investors dedicated to next-generation decarbonization technologies. Senior debt, in the form of green bonds, will be provided jointly by ECP ForeStar and Copenhagen Infrastructure Partners (CIP) through its Green Credit Fund. Subordinated debt will be provided by Japan Green Investment Corp. for Carbon Neutrality (“JICN”) and Aymium. Equity for the project will come from Hokuriku Electric Power Company, Nippon Steel Trading, and Aymium.
U.S. Ambassador to Japan Rahm Emanuel said: “A global threat like climate change demands a global solution. The only way to tackle a challenge of this magnitude is by thinking and collaborating across borders. With the United States and Japan cooperating on a multitude of areas related to energy and the environment, Aymium’s groundbreaking biocarbon production facility is the latest project to benefit from this flourishing relationship.”
Reiner Boehning, Managing Partner of ECP ForeStar said: “Aymium, together with its partners, has developed a proven production process that is an important building block to help decarbonize industrial processes, like steel making, and power generation. We are thrilled to be part of the investor group that finances the construction of Aymium’s next production facility in Williams, California.”
Jakob Groot, Partner at CIP and co-head of its Green Credit Fund, said: “We are proud to be part of this experienced lending consortium that is supporting Aymium in financing the construction of the Williams project and Hokuriku Electric in their continued decarbonization efforts. This financing represents an attractive opportunity for us and our investors to make yet another meaningful contribution to the green transition.”
Aymium produces the only commercially demonstrated carbon-negative product for replacing coal in power generation. Aymium’s renewable product is created through a non-combustion process that converts waste biomass to high purity biocarbon. The product is specifically engineered to immediately replace fossil coal without the need for any type of plant investment or process modification. The product has superior energy value, handling, and environmental attributes to coal. The process uses third-party certified sustainable waste biomass and is powered by self-generated renewable energy. Aymium’s process and product technologies are protected by more than 500 issued and pending patents. Aymium’s investors include Hokuriku Electric, Nippon Steel Trading, Rio Tinto and Steel Dynamics. Morgan Stanley served as debt arranger to Aymium in this transaction.
About Aymium
Aymium produces high-value biocarbon and biohydrogen products that can be used to immediately replace fossil fuels in the production of energy, metals, crops, and in the purification of water and air with no modifications to equipment or processes. Produced using sustainably sourced biomass – recovered and unusable wood – Aymium’s bioproducts are renewable, carbon-negative and they replace emission-heavy fossil fuels such as coal and coke. Aymium’s leading technology is backed by more than 500 issued or pending patents on a global basis. Aymium is headquartered in Minnesota, USA.
About Hokuriku Electric Power Company
Established in 1951, Hokuriku Electric Power Company is a comprehensive energy company that aims to contribute to the development of the Hokuriku region through the stable supply of affordable and high-quality energy. The company's vision for the future is to “develop together with Hokuriku and deliver new value nationwide and overseas,” and it is expanding its business beyond the existing electric power business while contributing to social issues such as addressing the global warming, sustainable development of the region, and the realization of a smart society.
About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focus on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.
CIP manages 12 funds and has to date raised approximately EUR 28 billion for investments in energy and associated infrastructure from more than 160 international institutional investors. CIP has approximately 500 employees and 12 offices around the world. For more information, visit www.cip.com.
About Japan Green Investment Corp. for Carbon Neutrality
Japan Green Investment Corp. for Carbon Neutrality (“JICN”) is a fund established through public-private partnership of the Japanese Government and Japanese private institutions, headquartered in Tokyo, JAPAN. JICN provides financing in the form of preferred equity investment and mezzanine or subordinated loans for startups and projects that contribute to the carbon neutrality as well as virtuous cycle between the environment and the economy.
About Nippon Steel Trading
Nippon Steel Trading Corporation is the core trading company of NIPPON STEEL CORPORATION Group, and was established in October 2013 through the merger of Nippon Steel Trading Co., Ltd. and Sumikin Bussan Corporation. The company continues to grow as a multiple specialty trading company operating four integrated core businesses: Steel, Industrial Supply & Infrastructure, Textiles, and Foodstuffs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606231738/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom